RxDoctor Payments Data

Michael Nabolotny, MD

Internal Medicine · Chicago, ILNPI 1225021470

Payments from drug & device makers

$920in general payments, 2019–2025

Across 44 payments — averaging $20.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$160
  • Boehringer Ingelheim$109
  • GSK$105
  • Amgen$97
  • Johnson & Johnson$81
  • Abbott$78
  • plus $290 from 9 others

What the payments were for

  • Food & beverage$82189%
  • Education$9911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$920 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$82,049
Medicare patients
305
Services billed
712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,145$435,846
XareltoRivaroxaban374$119,961
JanuviaSitagliptin Phosphate309$111,476
JardianceEmpagliflozin198$79,686
Invega SustennaPaliperidone Palmitate26$79,461
OzempicSemaglutide72$73,894
OrenciaAbatacept34$55,735
TrulicityDulaglutide45$48,608
TivicayDolutegravir Sodium20$47,597
Abilify MaintenaAripiprazole19$47,588
AustedoDeutetrabenazine11$45,980
XifaxanRifaximin14$44,043
RybelsusSemaglutide35$35,886
Divalproex Sodium661$29,697
Breo ElliptaFluticasone/Vilanterol65$28,218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$13$448,1141,182 claims
Johnson & JohnsonXarelto, Invega Sustenna$81$199,422400 claims
Novo NordiskOzempic, Rybelsus$67$109,780107 claims
Boehringer IngelheimJardiance$109$79,686198 claims
Lilly USA, LLCTrulicity$63$48,60845 claims
GSKBreo Ellipta, Incruse Ellipta$105$38,52493 claims
NovartisEntresto$23$18,92755 claims
Astellas Pharma US IncMyrbetriq$160$13,68840 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →